首页> 外文期刊>Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology >Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children.
【24h】

Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children.

机译:CD4(+)CD25(+)Foxp3(+)和分泌IL-10-的I型T调节细胞对簇状免疫疗法治疗儿童过敏性鼻炎的反应。

获取原文
获取原文并翻译 | 示例
           

摘要

We investigated the effects of cluster specific immunotherapy (SIT) with Dermatophagoides pteronyssinus (Der p) on CD4(+) CD25(+) Foxp3(+) Treg cells and IL-10-secreting type I T regulatory (Tr1) cells in Der p-sensitized children with allergic rhinitis (AR). We performed a prospective randomized study involving 46 children (aged 8-13 yr), of whom 25 children received Der p-SIT + pharmacotherapy and 21 received only pharmacotherapy, over a period of 1 yr. Prior to and at end of treatment, CD4(+) CD25(+) Foxp3(+) Treg cells and allergen-specific IL-10(+) IL-4(-) , IFN-γ(+) IL-4(-) , and IL-4(+) IFN-γ-CD4(+) T cells were measured by flow cytometry. Similarly, IL-4, IFN-γ, and IL-10 in supernatants from allergen-stimulated peripheral blood mononuclear cell (PBMC) cultures were measured by ELISA, and the suppressive effect of CD4(+) CD25(high) T cells on cell proliferation and cytokine release was estimated from both groups. Allergen-specific serum IgE and IgG4 were also assessed at the beginning and end of treatment by RAST and ELISA, respectively. The levels of allergen-specific Tr1 cells, IgG4, and allergen-induced IL-10 synthesis from PBMC cultures were significantly increased after SIT for 1 yr compared with baseline levels (p < 0.001 for all), with significant correlation between increased levels of Tr1 cells and improvements in nasal symptoms (r = 0.48, p < 0.05). In contrast, the levels of CD4(+) CD25(+) Foxp3(+) T cells, allergen-specific Th1 and Th2 cells, the production of IL-4 and IFN-γ, and the function of CD4(+) CD25(high) T cells were not altered in either group at the end of treatment. These data suggest that the up-regulation of Tr1 cells may play an important role in SIT and be a useful marker of successful SIT in AR patients.
机译:我们研究了Dermatophagoides pteronyssinus(Der p)的簇特异性免疫疗法(SIT)对Der p-中CD4(+)CD25(+)Foxp3(+)Treg细胞和IL-10-分泌型IT调节(Tr1)细胞的影响。过敏性鼻炎(AR)的致敏儿童。我们进行了一项前瞻性随机研究,涉及46名儿童(8-13岁),其中25名儿童在1年内接受了Der p-SIT +药物治疗,而21名仅接受药物治疗。治疗之前和结束时,CD4(+)CD25(+)Foxp3(+)Treg细胞和过敏原特异性IL-10(+)IL-4(-),IFN-γ(+)IL-4(- )和IL-4(+)IFN-γ-CD4(+)T细胞通过流式细胞仪测量。同样,通过ELISA测定过敏原刺激的外周血单个核细胞(PBMC)培养上清液中的IL-4,IFN-γ和IL-10,并且CD4(+)CD25(high)T细胞对细胞的抑制作用两组均评估了增殖和细胞因子释放。在治疗开始和结束时,还分别通过RAST和ELISA评估了过敏原特异性血清IgE和IgG4。与基线水平相比,SIT治疗1年后,PBMC培养物的变应原特异性Tr1细胞,IgG4和变应原诱导的IL-10合成水平显着增加(所有情况均p <0.001),且Tr1升高水平之间存在显着相关性细胞和鼻部症状的改善(r = 0.48,p <0.05)。相反,CD4(+)CD25(+)Foxp3(+)T细胞,过敏原特异性Th1和Th2细胞的水平,IL-4和IFN-γ的产生以及CD4(+)CD25(高)在治疗结束时,两组中的T细胞均未改变。这些数据表明,Tr1细胞的上调可能在SIT中起重要作用,并且是AR患者SIT成功的有用标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号